ArticleObesity surgery2026
Cost-Effectiveness Analysis of Bariatric Surgery and Pharmacological Treatments for People with Obesity and Type 2 Diabetes Mellitus.
Article in Obesity surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesObesity and its associated type 2 diabetes mellitus (T2DM) represent a growing public health challenge worldwide. This study aimed to evaluate the cost-effectiveness of sleeve gastrectomy (SG) compared with pharmacological therapy (PT) in patients with obesity and T2DM from the perspective of the reimbursement institution in Türkiye.
methodsA Markov cohort model was developed to evaluate the cost-effectiveness of SG compared with PT in patients with obesity and T2DM. The model simulated a cohort of 1,000 individuals entering the model at age 40 years over a 60-year lifetime horizon from the perspectives of the Social Security Institution (SGK) and the Public Health Service Price Schedule (PHSP). Cost data were obtained from hospital records of 44 patients receiving PT and 55 patients undergoing SG, while effectiveness inputs were derived from published literature. Costs were calculated for the 2023 price year, and both costs and health outcomes were discounted at an annual rate of 3%. One-way and probabilistic sensitivity analyses were performed to assess parameter uncertainty.
resultsAccording to the Markov model results, lifetime total costs were estimated at US$3,412.9 for PT and US$4,043.8 for SG. Lifetime health outcomes, measured in quality-adjusted life years (QALYs), were 11.33 for PT and 12.68 for SG. Compared with PT, SG provided an additional 1.35 QALYs at an incremental cost of US$630.9, corresponding to an incremental cost-effectiveness ratio (ICER) of US$467 per QALY gained.
conclusionsThe results indicate that SG is a cost-effective treatment option for patients with obesity and T2DM in Türkiye, providing greater health benefits at an acceptable incremental cost compared with PT. The relatively lower healthcare costs in Türkiye may further enhance the long-term cost-effectiveness of SG.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.